The U.S. Court of Appeals for the Federal Circuit overturned a ruling in favor of AngioScore in a patent infringement case between it and TriReme Medical and a pair of related companies.
The court ruled that an earlier decision from the United States District Court for the Northern District of California “improperly exercised supplemental jurisdiction over state-law claims,” but not in denying attorney fees.
The earlier decision was reversed-in-part, according to court documents, while denial to attorney fees was affirmed-in-part. The case was remanded “with instructions to dismiss the state-law claims for lack of jurisdiction.”
In July, a federal appeals court tossed out AngioScore‘s $20 million win over TriReme Medical and a pair of related companies, ruling that the case never should have made it to the federal level.
Over a year ago, Judge Yvonne Gonzalez Rogers of the U.S. District Court for Northern California ruled that AngioScore founder Eitan Konstantino violated his duties to AngioScore when he started rival companies TriReme, Quattro Vascular and QT Vascular (SGX:5I0). (AngioScore ultimately lost a related patent infringement lawsuit brought by TriReme in 2014).
AngioScore, which Spectranetics (NSDQ:SPNC) acquired in 2014 for $230 million, accused Konstantino of breaching his fiduciary duties when he developed TriReme’s Chocolate balloon catheter, which competes directly with AngioScore’s AngioSculpt balloon. The Chocolate device won 510(k) clearance from the FDA in June 2014. The lawsuit also accused TriReme, Quattro and QT Vascular of abetting in Konstantino’s alleged breaches.
